Clinical Trials/NCT01259882

NCT01259882

Completed

Phase 1

A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers

Pfizer1 site in 1 country61 target enrollmentDecember 2010

ConditionsPain

InterventionsPF-05089771

DrugsPF-05089771

Overview

Phase: Phase 1
Intervention: PF-05089771
Conditions: Pain
Sponsor: Pfizer
Enrollment: 61
Locations: 1
Primary Endpoint: Tmax = Time of maximum concentration of PF-05089771 in plasma (hr)
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a two part study. The purpose of the first part is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following single escalating doses. Secondary objectives will be to investigate the PK of an alternative formulation of PF-05089771 and the effect of food on the PK of PF-05089771. The second part of the study will focus on investigation of the exploratory pharmacodynamics of PF-05089771 using novel biomarkers in healthy volunteers. The doses selected in Part B will have been administered previously in Part A of the study.

Registry

clinicaltrials.gov

Start Date

December 2010

End Date

September 2011

Last Updated

14 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Pfizer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy male subjects or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive.
•Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
•An informed consent document signed and dated by the subject
•Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

•Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
•Any condition possibly affecting drug absorption (e.g., gastrectomy).
•A positive urine drug screen.
•History of regular alcohol consumption exceeding 21 drinks/week (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
•Treatment with an investigational drug within 60 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
•12-lead ECG demonstrating QTc \>450 msec at screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
•Females of child bearing potential.
•Use of prescription or non-prescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
•Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing. History of sensitivity to heparin or heparin-induced thrombocytopenia.
•Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.

Arms & Interventions

Cohort 1: Experimental intervention: PF-05089771 or placebo

Cohort 1

Intervention: PF-05089771

Cohort 2: Experimental intervention: PF-05089771 or placebo

Cohort 2

Intervention: PF-05089771

Cohort 3: Experimental intervention: PF-05089771 or placebo

Cohort 3

Intervention: PF-05089771

Cohort 4: Experimental intervention: PF-05089771 or placebo

Cohort 4

Intervention: PF-05089771

Cohort 5: Experimental intervention: PF-05089771 or placebo

Cohort 5

Intervention: PF-05089771

Cohort 6: Experimental intervention: PF-05089771 or placebo

Cohort 6

Intervention: PF-05089771

Outcomes

Primary Outcomes

Tmax = Time of maximum concentration of PF-05089771 in plasma (hr)

Time Frame: Days 1-3

MRT = Mean residence time of PF-05089771 in the body (hr)

Time Frame: Days 1-3

Maximum concentration (Cmax) for PF-05089771 in plasma (measured in ng/mL)

Time Frame: Days 1-3

Number of participants with adverse events as a measure of safety and tolerability of PF-05089771.

Time Frame: Days 1-3

AUClast = Area under the curve from the time of dosing to the last data point taken (ng.hr/mL)

Time Frame: Days 1-3

Secondary Outcomes

Heat Pain Perception Threshold (HPPT). Measured by applying a heat thermode to the thigh for 1 minute at 47oC. HPPT will be measured at 3 separate doses plus placebo in 12 healthy volunteers.(Hours 1-6 post dose.)
Urine: Aet (amount excreted in urine), Aet% and CLr for selected doses dependent on the emerging pharmacokinetics of PF-05089771 where t = 24 hours.(Up to 24 hours)
AUC24 = Area under the curve from the time of dosing to 24 hours post dose (ng.hr/mL)(Days 1-3)
Odor threshold (Sniffin' Sticks). Measured with Sniffin Sticks. Will be measured at 3 separate doses plus placebo in 12 healthy volunteers(Hours 1-6 post dose.)
CI/F = Clearance of PF-05089771 from plasma corrected for systemic compound availability (L/hr)(Days 1-3)
Long Thermal Stimulation (LTS). Measured by applying a heat thermode to the thigh at 48oC for 5 seconds. will be measured at 3 separate doses plus placebo in 12 healthy volunteers(Hours 1-6 post dose.)
AUCinf = Area under the curve from the time of dosing extrapolated to infinity (ng.hr/mL)(Days 1-3)
t½ = Elimination half life of PF-05089771 (hr)(Days 1-3)
C8 hour = concentration of PF-05089771 in the plasma 8 hours post dose (ng/mL)(Days 1-3)